

## BioCorRx, Inc. Announces First Patients Treated in Wellness Center Pilot Using the Start Fresh Program

Los Angeles, July 6, 2015 (GLOBE NEWSWIRE) --BioCorRx, Inc. (BICX), developer of the Start Fresh Program, announces update on the Company's pilot program with Myriad Medical Marketing (MMM). The first location in the pilot program, Corona Physical Medicine (CPM), has just treated their first three patients using the Start Fresh Program. CPM is located at 1150 El Camino Avenue, Suite 108, Corona, CA 92879.

Upon successful completion of the pilot program, MMM will begin to introduce the Start Fresh Program to other wellness centers nationwide. The original plan was to run the pilot in up to five centers, however, MMM has since decided that resources would be better utilized by focusing on one center. "We are thrilled to see the first patients being treated using our program at Corona Physical Medicine. It took a little longer than anticipated to get the pilot program running due to the intense level of training and coordination required to ensure that each patient has a great and safe experience. This pilot program is a completely different distribution model than we are accustomed to, however, the overall potential is exciting should it be deemed viable by all parties involved," stated COO & interim CEO, Brady Granier.

CPM is a holistic wellness center owned by Dr. Jon Brunelle, founder of MMM. CPM's philosophy of integrative medicine can be highly beneficial to patients who undergo the Start Fresh Program. The center offers holistic medical services, delivered by medical doctors and other practitioners, which include chiropractic care, acupuncture, massage, nutrition, and hydration therapy among other services. "We are very pleased to have had treated our first few patients at Corona Physical Medicine. We plan to treat more in the coming weeks," stated Dr. Brunelle. "With all of Myriad's resources focused on the pilot program at our Corona location, we feel that we can better test and optimize the process before taking it to other locations. We are focused on creating a system that can be easily duplicated in other locations," added Dr. Brunelle.

Visit BioCorRx, Inc.'s investor relations website at<u>www.BICXcorp.com</u> to receive the most up to date company information.

<u>Click here to view Recent National Television Media on the BioCorRx YouTube</u>
<u>Channel</u>

Click here for company Facebook page for more stories and media coverage

## About BioCorRx, Inc.

BioCorRx, Inc. ® (OTCQB: BICX) is an addiction treatment and rehabilitation company offering a unique approach to the treatment of substance abuse addiction. The Start Fresh

Program®, a medication-assisted treatment program, consists of two components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers therapeutic levels of the drug Naltrexone, an opioid antagonist that significantly reduces physical cravings for alcohol and opioids, into the body. The second component of the program developed by BioCorRx, Inc. is a one on one coaching program specifically tailored for the treatment of alcoholism and other substance abuse addictions. Clinic reports show that the treatment program can be successful for individuals who complete the program. For more information on BICX, visit www.BioCorRx.com

## Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

CONTACT: Investor Relations

SmallCapVoice.com, Inc.

512-267-2430

Source: BioCorRx